Chen, Qing
Li, Yan
Zhang, Wenjie
Wang, Chen
Yang, Shengjie
Guo, Qisen http://orcid.org/0000-0003-4304-6431
Funding for this research was provided by:
Shandong Key Research and Development Program (2019GSF108251)
Article History
Received: 7 August 2021
Accepted: 11 November 2021
First Online: 19 November 2021
Declarations
:
: All authors declare no conflicts of interest associated with this manuscript.
: This retrospective study was performed using data from anonymized patients who received ICIs plus anlotinib treatment between January 2019 and December 2020. Because of the nature of retrospective design and patient anonymization, the ethical board of the Institutional Ethics Committee of the Shandong First Medical University and Shandong Academy of Medical Sciences approved the retrospective study.
: The need for written informed consent was waived due to the retrospective nature of the study.
: All authors have consented to publication of the results presented in this manuscript.